Paul Schimmel

Paul Schimmel General Information

Description

Mr. Paul Schimmel serves as Board Member at aTyr Pharma. He, Ph.D. has served as a director since September 2005. He is currently a director of Alnylam Pharmaceuticals, Inc. (Alnylam), a biopharmaceutical company (from which he is retiring at Alnylam's 2020 Annual Meeting of Stockholders), as well as a director of several private companies. He serves as Scientific Advisor & Board Member at Tevard Biosciences. He co-founded and served as a Member of the Scientific Advisory Board at Metabolon. He was a co-founder of Repligen Corporation, Alkermes, Inc. He served as Board Member at Kindex. Cubist Pharmaceuticals, Sirtris Pharmaceuticals, and Alnylam, and a founding Director of Momenta, Inc. He is Ernest and Jean Hahn Professor of Molecular Medicine and of Chemistry at Scripps Research. He also serves as an Advisor & Venture Partner at Cardinal Partners. He was formerly the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at the Massachusetts Institute of Technology. He holds a B.A. from Ohio Wesleyan University and a Ph.D. in biochemistry and biophysics from the Massachusetts Institute of Technology. He is an elected member of the National Academy of Sciences, the National Academy of Medicine, the National Academy of Inventors, the American Philosophical Society, and the American Academy of Arts and Sciences.